Back to results
US 10,946,080 B2Granted
Compositions and methods for combination therapy with dengue virus and dendritic cells
AssigneePrimevax Immuno-Oncology, Inc.
InventorBruce W. Lyday
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
Claims20
A method for reducing or treating cancer, comprising:
- (a) subcutaneously administering to a subject an effective amount of Dengue Virus as an adjuvant to an immunotherapy for treatment of cancer, wherein the Dengue Virus is present in a concentration of from 103 pfu/ml to 108 pfu/ml, and wherein the subject has a cancer;
- and
- (b) administering autologous dendritic cells to the subject.
A method for reducing or treating cancer, comprising:
- (a) subcutaneously administering to a subject an effective amount of Dengue Virus as an adjuvant to an immunotherapy for treatment of cancer, wherein the Dengue Virus is present in a concentration of from 103 pfu/ml to 108 pfu/ml, and wherein the subject has a cancer;
- and
- (b) administering allogeneic dendritic cells to the subject.
Dependencies are inferred from the claim text.